Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. shows a slight decrease today, losing -€0.010 (-0.740%) compared to yesterday.
We see a rather positive sentiment for Akebia Therapeutics Inc. with 12 Buy predictions and 1 Sell predictions.
Based on the current price of 1.34 € the target price of 6 € shows a potential of 348.77% for Akebia Therapeutics Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Akebia Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | -0.740% | 1.660% | -3.024% | -23.941% | -26.434% | 225.913% | -45.244% |
| Ardelyx Inc. | -1.380% | -2.416% | -3.297% | 11.041% | -0.745% | 166.985% | -14.652% |
| Krystal Biotech | -1.540% | -2.048% | 11.829% | 26.035% | 31.997% | 166.093% | - |
| Evolus Inc | -1.680% | 2.586% | -0.833% | -45.413% | -43.333% | -8.462% | 63.596% |
Comments
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at BTIG Research from $10.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia (AKBA) Q2 Revenue Jumps 43%
Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news
